Each filer's latest filing for 10567X101 since 12/18/2024, largest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Orbimed Advisors LLC
13D/A
|
13.5% |
9/10/2026
Event 9/8/2026
|
|
| Orbimed Advisors LLC | 13.5% | ||
| OrbiMed Capital GP IX LLC | 13.2% | ||
| OrbiMed Genesis GP LLC | 0.3% | ||
|
Forbion Growth Opportunities Fund III Cooperatief U.A.
13G
|
12.9% |
11/16/2026
Event 9/30/2026
|
|
| Forbion Growth Opportunities Fund III Cooperatief U.A. | 12.9% | ||
| Forbion Growth III Management B.V. | 12.9% | ||
| Forbion Ventures Fund VII Cooperatief U.A. | 11.3% | ||
| Forbion Ventures VII Management B.V. | 11.3% | ||
|
AH Bio Fund IV, L.P.
13D
|
11.4% |
8/14/2026
Event 8/7/2026
|
|
| AH Bio Fund IV, L.P. | 11.4% | ||
| AH Equity Partners Bio IV, L.L.C. | 11.4% | ||
| Marc L. Andreessen | 11.4% | ||
| Benjamin A. Horowitz | 11.4% | ||
| Travis Murdoch 13G | 9.3% |
11/16/2026
Event 9/30/2026
|
|
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. 13G | 8.2% |
11/9/2026
Event 9/30/2026
|
|
|
FMR LLC
13G
|
8.2% |
11/5/2026
Event 9/30/2026
|
|
| FMR LLC | 8.2% | ||
| Abigail P. Johnson | 8.2% | ||
|
Frazier Life Sciences Public Fund, L.P.
13G
|
5.5% |
8/14/2026
Event 8/7/2026
|
|
| Frazier Life Sciences Public Fund, L.P. | 5.5% | ||
| FHMLSP, L.P. | 5.5% | ||
| FHMLSP, L.L.C. | 5.5% | ||
| Frazier Life Sciences XI, L.P. | 0% | ||
| FHMLS XI, L.P. | 0% | ||
| FHMLS XI, L.L.C. | 0% | ||
| Frazier Life Sciences XII, L.P. | 0.1% | ||
| FHMLS XII, L.P. | 0.1% | ||
| FHMLS XII, L.L.C. | 0.1% |
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 64 | 73.4 M | $1.48B |